WVE (WAVE Life Sciences) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WVE WAVE Life Sciences Ltd WVE
59 GF Score
Price $6.04
GF Value $4.36
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is WAVE Life Sciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

WAVE Life Sciences Quality Rank Related Terms

WVE
59GF Score
WAVE Life Sciences Ltd WVE
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is WAVE Life Sciences (WVE) Overvalued in 2026?

Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued. The current stock price of $6.04 is trading 38.4% above its estimated GF Value™ of $4.36. GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.

Key valuation signals for WVE:

  • Quality Rank:
  • GF Value™: $4.36 vs. price of $6.04 (38.4% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WAVE Life Sciences Business Description

Other Exchanges 1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score

Get the complete analysis for WVE

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.04
Price
$4.36
GF Value